RAPS: FDA: Generic Opioids Must be \'No Less\' Abuse-Deterrent Than Brand-Name Versions

25.03.2016

The US Food and Drug Administration (FDA) released a new draft guidance intended to ensure that generic versions of abuse-deterrent opioids meet the same standards for abuse deterrence as their brand-name counterparts for public comment on Thursday.